Compare · FLGT vs HUM
FLGT vs HUM
Side-by-side comparison of Fulgent Genetics Inc. (FLGT) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FLGT and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $51.90B, about 88.4x FLGT ($587.2M).
- Over the past year, FLGT is down 12.4% and HUM is up 50.2% - HUM leads by 62.6 points.
- HUM has been more active in the news (13 items in the past 4 weeks vs 1 for FLGT).
- HUM has more recent analyst coverage (25 ratings vs 9 for FLGT).
- Company
- Fulgent Genetics Inc.
- Humana Inc.
- Price
- $19.85-6.81%
- $413.06-4.40%
- Market cap
- $587.2M
- $51.90B
- 1M return
- -9.11%
- +7.44%
- 1Y return
- -12.42%
- +50.19%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 1
- 13
- Recent ratings
- 9
- 25
Fulgent Genetics Inc.
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home COVID-19 test capabilities. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest FLGT
- Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026
- CFO and Treasurer Kim Paul covered exercise/tax liability with 2,087 shares, decreasing direct ownership by 0.58% to 356,543 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Hsieh Ming covered exercise/tax liability with 4,392 shares, decreasing direct ownership by 0.49% to 885,952 units (SEC Form 4) to satisfy tax liability
- Chief Scientific Officer Gao Hanlin sold $32,885 worth of shares (1,673 units at $19.66), decreasing direct ownership by 0.17% to 986,117 units (SEC Form 4) (withholding tax)
- President and COO Xie Jian sold $41,809 worth of shares (2,127 units at $19.66), decreasing direct ownership by 0.59% to 359,924 units (SEC Form 4) to satisfy withholding obligation
- Chief Executive Officer Hsieh Ming covered exercise/tax liability with 2,949 shares, decreasing direct ownership by 0.33% to 890,344 units (SEC Form 4) (withholding obligation)
- CFO and Treasurer Kim Paul covered exercise/tax liability with 1,168 shares, decreasing direct ownership by 0.32% to 358,630 units (SEC Form 4) to satisfy tax liability
- President and COO Xie Jian sold $23,747 worth of shares (1,193 units at $19.91), decreasing direct ownership by 0.33% to 362,051 units (SEC Form 4) to satisfy withholding tax
- Chief Scientific Officer Gao Hanlin sold $18,691 worth of shares (939 units at $19.91), decreasing direct ownership by 0.09% to 987,790 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 10-Q filed by Fulgent Genetics Inc.
Latest HUM
- Humana Announces New Strategic Joint Venture with BlackRock to Manage CenterWell Senior Primary Care Clinics
- SEC Form 8-K filed by Humana Inc.
- Humana Inc. to Release Third Quarter 2026 Results on November 6, 2026
- Humana upgraded by Raymond James with a new price target
- After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports
- Humana upgraded by Robert W. Baird with a new price target
- Humana Announces Improved CMS Star Ratings with 95 Percent of Medicare Advantage Members in 4-Star or Above Plans for 2027
- SEC Form 8-K filed by Humana Inc.
- Humana upgraded by Cantor Fitzgerald with a new price target
- Humana Generates Nearly $20 Billion in Economic Impact Across Kentucky, New Report Finds